Drug
Glycopyrrolate clinical trials
Also written NVA237, glycopyrronium bromide, CHF 5259 and Robinul.
- studies test it
- 130
- open now
- 6
- in phase 3
- 41
- first study started
- 2005
Keep track of what changes. Save the Glycopyrrolate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
130 studies that test it; most in 2014 (14)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 5 |
| 2009 | 5 |
| 2010 | 8 |
| 2011 | 5 |
| 2012 | 13 |
| 2013 | 7 |
| 2014 | 14 |
| 2015 | 11 |
| 2016 | 12 |
| 2017 | 11 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 5 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 21
- Phase 2
- 36
- Phase 3
- 41
- Phase 4
- 25
- No phase
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 83 · Other 47
Novartis Pharmaceuticals (24) · Pearl Therapeutics, Inc. (19) · Chiesi Farmaceutici S.p.A. (16) · AstraZeneca (6) · Novartis (6) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (3) · James J. Peters Veterans Affairs Medical Center (3) · Zhuan Zhang (2)
Often tested with
Tested in the same studies.
Formoterol (23) · Neostigmine (16) · Indacaterol (11) · Budesonide (10) · Sugammadex (10) · Beclomethasone (6) · Tiotropium (6) · PT003 (5)
Studies
Open first, then newest update. How each study uses Glycopyrrolate is read from its arms, and is right about nine times in ten.
Testing it · 130
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseRecruitingPhase 3AstraZenecaNCT06283966Written as BGF MDI 320/14.4/9.6 μg
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and HyperinflationRecruitingPhase 4AstraZenecaNCT07073950Written as Budesonide/Glycopyrronium/Formoterol Fumarate
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With AsthmaRecruitingPhase 2Novartis PharmaceuticalsNCT05222529Written as Glycopyrronium bromide 25ug
- Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural PunctureRecruitingPhase 2Mayo ClinicNCT05116930Written as Glycopyrrolate
- A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible BronchoscopyNot yet recruitingPhase 2/3Post Graduate Institute of Medical Education and Research, ChandigarhNCT06376942Written as Glycopyrronium
- Antiperistaltic Effect and Safety of Glycopyrronium for Colonoscopic PolypectomyEnrolling by invitationPhase 1/2Jie ChenNCT06041984Written as Glycopyrrolate
- Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDSuspendedNot applicableMedical University of BialystokNCT07541378Written as Glycopyrronium
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT04320342Written as Glycopyrronium Bromide
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)CompletedPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07016412Written as Glycopyrrolate 21.25 mcg
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPDCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT01917331Written as Beclometasone/Formoterol/Glycopyrrolate
- Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCICompletedEarly Phase 1James J. Peters Veterans Affairs Medical CenterNCT02370862Written as Neostigmine and Glycopyrrolate
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)CompletedPhase 3AstraZenecaNCT04609904Written as BGF MDI 320/28.8/9.6 μg
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)CompletedPhase 3AstraZenecaNCT04609878Written as BGF MDI 320/28.8/9.6 μg
- Effect of Perioperative Use of Glycopyrrolate on Lung Function in Patients Under General AnesthesiaCompletedNot applicableZhuan ZhangNCT05693246Written as Glycopyrrolate
- Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)CompletedPhase 2Chiesi Farmaceutici S.p.A.NCT02296411Written as CHF 5259 12.5 µg + Qvar
- Functional Respiratory Imaging Study (DARWiIN)CompletedPhase 3Chiesi Farmaceutici S.p.A.NCT04876677Written as Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium (BDP/FF/GB)
- A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPDCompletedPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT06545500Written as Glycopyrrolate (85 μg)
- Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover StudyCompletedPhase 4Thammasat UniversityNCT06905483Written as Budesonide/Glycopyrronium/Formoterol (BGF)
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07132983Written as Glycopyrrolate 42.5 mcg
- The Impact of Sugammadex on Ileus After Abdominal Wall ReconstructionCompletedPhase 4Clayton PetroNCT05985343Written as Neostigmine / Glycopyrrolate
See all 130 studies that test Glycopyrrolate →
Given in every arm · 8 — Glycopyrrolate is usual care beside what is tested
- Absorption of Indacaterol and Glycopyrronium From Ultibro BreezhalerCompletedPhase 1Orion Corporation, Orion PharmaNCT04856098Written as Indacaterol maleate and glycopyrronium bromide
- Chronotropic Incompetence in Patients With HFpEFCompletedNot applicableUniversity of Texas Southwestern Medical CenterNCT02524145Written as Glycopyrrolate
- Dexmedetomidine and Propofol for Pediatric MRI SedationCompletedPhase 4Medical College of WisconsinNCT03513757Written as Glycopyrrolate
- Decision Support for Intraoperative Low Blood PressureCompletedNot applicableVanderbilt University Medical CenterNCT02726620Written as Glycopyrrolate
- Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic CholecystectomyCompletedPhase 4B.P. Koirala Institute of Health SciencesNCT02327923Written as Glycopyrrolate
- Anesthetics in Rhytidoplasty - A Comparison StudyCompletedNot applicableMercy Facial Plastic Surgery CenterNCT02410460Written as glycopyrrolate
- Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD PatientsCompletedPhase 4University of MilanNCT02181023Written as Glycopyrronium Bromide
- Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular BlockCompletedPhase 4University of California, San FranciscoNCT01199237Written as Glycopyrrolate
As the comparator · 24 — what is tested is compared with Glycopyrrolate
- Sugammadex-Induced Clenching During Neuromuscular Blockade ReversalRecruitingNot applicableWonkwang University HospitalNCT06962007Written as Pyridostigmine/Glycopyrrolate Group
- Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD PatientsCompletedPhase 1AeroRx Therapeutics Inc.NCT07802730Written as Glycopyrrolate (18 mcg)
- Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine SurgeryCompletedPhase 4University of Missouri-ColumbiaNCT05887375Written as Glycopyrrolate
- Sugammadex vs Neostigmine Reversal in Pediatric AppendectomyTerminatedPhase 4Emory UniversityNCT05256901Written as Neostigmine/Glycopyrrolate
- Sugammadex v.s. Neostigmine/GlycopyrrolateCompletedNot applicableNational Taiwan University HospitalNCT06398899Written as Group N: neostigmine/glycopyrrolate
- ANTES B+ Clinical TrialTerminatedPhase 4Fundacio Privada Mon Clinic BarcelonaNCT06282861Written as Seebri
- Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)CompletedPhase 4Merck Sharp & Dohme LLCNCT03909165Written as Neostigmine + Glycopyrrolate
- Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary HyperhidrosisWithdrawnPhase 2Dr. August Wolff GmbH & Co. KG ArzneimittelNCT04159610Written as Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
- Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of RocuroniumCompletedPhase 4Ciusss de L'Est de l'Île de MontréalNCT05718934Written as Neostigmine and glycopyrrolate
- Sugammadex Versus Neostigmine for Reversal of Rocuronium NeuromuscularCompletedPhase 4The Cleveland ClinicNCT03322657Written as Glycopyrrolate
- Use of High Resolution Colonic Manometry in Studying MotilityWithdrawnPhase 1James J. Peters Veterans Affairs Medical CenterNCT02574611Written as Glycopyrrolate
- Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)CompletedPhase 4Merck Sharp & Dohme LLCNCT03351608Written as Neostigmine + Glycopyrrolate
- Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)CompletedPhase 4Merck Sharp & Dohme LLCNCT03346070Written as Neostigmine + Glycopyrrolate
- Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)CompletedPhase 4Merck Sharp & Dohme LLCNCT03346057Written as Neostigmine + Glycopyrrolate
- Investigation of Sugammadex in Outpatient Urological ProceduresCompletedPhase 4M.D. Anderson Cancer CenterNCT03138967Written as Glycopyrrolate
- Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Pediatric Emergence Delirium in Sevoflurane-rocuronium AnesthesiaCompletedPhase 4Pusan National University Yangsan HospitalNCT03229486Written as Neostigmine+Glycopyrronium
- Study to Determine if Administration of Sugammadex Impacts Hospital EfficiencyCompletedPhase 4University of South FloridaNCT02860507Written as Glycopyrrolate
- Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)CompletedPhase 3Merck Sharp & Dohme LLCNCT00473694Written as glycopyrrolate
- Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)CompletedPhase 3Merck Sharp & Dohme LLCNCT01479764Written as Glycopyrrolate
- A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.CompletedPhase 3Novartis PharmaceuticalsNCT01727141Written as NVA237
Showing 20 of 24.
Codes
What other systems call Glycopyrrolate · ClinicalTrials.gg INT007576
- MeSH (NLM) D006024GlycopyrrolateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) V92SO9WP2IGLYCOPYRROLATEConfirmed FDA, NLM
- RxNorm 4955One source FDA
- NCI Thesaurus C29078GlycopyrrolateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D006024 | Glycopyrrolate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | V92SO9WP2I | GLYCOPYRROLATE | Confirmed FDA, NLM |
| RxNorm | 4955 | — | One source FDA |
| NCI Thesaurus | C29078 | Glycopyrrolate | One source FDA |
Also registered as glycopyrronium (UNII A14FB57V1D · RxNorm 1546438).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.